Latest Conference Articles

October 22nd 2023, 7:45pm

ESMO Congress

Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

October 22nd 2023, 6:57pm

ESMO Congress

Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.

October 22nd 2023, 6:41pm

ESMO Congress

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

October 22nd 2023, 6:36pm

ESMO Congress

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

October 22nd 2023, 5:45pm

ESMO Congress

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

October 22nd 2023, 5:35pm

ESMO Congress

The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

October 22nd 2023, 2:35pm

ESMO Congress

Pembrolizumab plus enzalutamide provided no radiographic progression-free survival or overall survival improvements vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

October 21st 2023, 10:17pm

ESMO Congress

Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.

October 21st 2023, 10:00pm

OncLive News Network: On Location at ESMO 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

October 21st 2023, 8:35pm

ESMO Congress

Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.

October 21st 2023, 8:12pm

ESMO Congress

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

October 21st 2023, 7:49pm

ESMO Congress

The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.

October 21st 2023, 7:28pm

ESMO Congress

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

October 21st 2023, 7:19pm

ESMO Congress

Treatment with the oral ALK inhibitor alectinib led to a statistically significant improvement in disease-free survival in patients with resected ALK-positive non–small cell lung cancer.

October 21st 2023, 7:00pm

ESMO Congress

Treatment with belzutifan produced improvements in progression-free survival and objective response rate vs everolimus in patients with pretreated advanced clear cell renal cell carcinoma.

October 21st 2023, 6:44pm

ESMO Congress

Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.

October 21st 2023, 6:38pm

ESMO Congress

Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.

October 21st 2023, 6:28pm

ESMO Congress

Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma.

October 21st 2023, 6:24pm

ESMO Congress

Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.

October 21st 2023, 6:06pm

ESMO Congress

Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease